Dianthus Therapeutics (DNTH) Guggenheim’s Inaugural Healthcare Innovation Conference summary

Company overview and strategy

• Focused on next-generation complement therapeutics, with DNTH103 as the lead program, a potent C1s inhibitor designed for biweekly autoinjector administration.

• 2024 marked by execution, with phase II programs initiated for myasthenia gravis (MG) and multifocal motor neuropathy (MMN).

• Announced transition to a phase III pivotal program in CIDP, with FDA agreement, aiming to start by year-end.

• CIDP phase III will include treatment-naive, stable, and IVIG-refractory patients, using a two-part design with open-label and placebo-controlled phases.

• Enrollment and patient selection will be supported by investigator training and an independent review board.

Clinical development and competitive positioning

• DNTH103 offers a differentiated dosing regimen: 300 mg every two weeks, compared to competitors requiring more frequent or higher-volume dosing.

• Head-to-head in vitro studies show DNTH103 is significantly more potent than Riliprubart, with sevenfold higher potency in key assays.

• Safety profile aims to match or exceed that of first-generation C1s inhibitors, with no boxed warning or REMS program anticipated.

• Market strategy targets first-line use in complement inhibitor class, with a focus on convenience and safety as key differentiators.

• MMN market is smaller but highly relevant, as FcRNs are ineffective and DNTH103 could be the leading option.

Market opportunity and timelines

• MMN patient population estimated at 5,000–10,000, with potential for growth as awareness increases; CIDP estimates have risen to 40,000–58,000 in the U.S.

• MG is considered the largest commercial opportunity, supporting multi-billion dollar franchises.

• Data readouts expected: MG in second half of 2025, MMN by end of 2026, and CIDP within the cash runway extending to the second half of 2027.

• Phase II MG study tests two doses, with efficacy benchmarked against ULTOMIRIS and MG-ADL as a key endpoint.

• Phase III MG trial will be larger, likely single-dose, with MG-ADL as the primary endpoint.